NEU-411 clinical trials

A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease

This study is looking into a new medication called NEU-411 for people aged 40-80 with early Parkinson's disease. It focuses on those with a specific genetic marker. The aim is to see if the drug is safe and effective in slowing the disease's progress.